Free tool
FAERS Monitor: Datroway
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761394 or its brand name (Datroway, Datopotamab Deruxtecan-Dlnk). Reports on generic versions are filed under their own applications.
Reports
859
Serious
553
64% of reports
Hospitalization
137
Death reported
173
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression256
- stomatitis146
- off label use122
- death51
- no adverse event46
- nausea40
- fatigue33
- dry eye32
- interstitial lung disease31
- dyspnoea26
- rash24
- pneumonitis23
- cough21
- alopecia19
- mucosal inflammation19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 321 |
| 2026 | 530 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,300 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stomatitisSignal | 146 | 59.1 | 51.0 | 8,282 |
| disease progressionSignal | 256 | 53.1 | 47.9 | 13,077 |
| pneumonitisSignal | 23 | 20.7 | 13.8 | 412 |
| mucosal inflammationSignal | 19 | 17.8 | 11.4 | 285 |
| dry eyeSignal | 32 | 15.7 | 11.2 | 427 |
| interstitial lung diseaseSignal | 31 | 15.7 | 11.1 | 412 |
| no adverse eventSignal | 46 | 6.2 | 4.7 | 198 |
| off label useSignal | 122 | 3.4 | 2.9 | 214 |
| alopeciaSignal | 19 | 2.4 | 1.5 | 14 |
| cough | 21 | 1.8 | 1.2 | 7 |
| death | 51 | 1.4 | 1.1 | 7 |
| rash | 24 | 1.3 | 0.9 | 2 |
| nausea | 40 | 1.2 | 0.9 | 2 |
| dyspnoea | 26 | 1.1 | 0.8 | 0 |
| fatigue | 33 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.